- Oculus Innovative Sciences (OCLS +27%) says Mexican regulators approved its Microcyn60 Oral Care family of products intended for use as an adjunct treatment in mouth and throat infections.
- OCLS says the commercialization of its Microcyn technology for the new indication lays the foundation for its introduction into other international markets, particularly Europe.
- The first oral care product to be launched by OCLS' Latin American partner, More Pharma, will be Microdacyn60 Bucofaringeo.
Oculus +27% as oral, throat infection products gain approval in Mexico
Feb 19 2014, 10:47 ET